Work in Progress: Drugs in Development

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis, fibrosis, and potential liver failure.
• Current approved treatments, ursodeoxycholic acid and obeticholic acid, have limitations in efficacy and tolerability for many patients.
• A significant unmet need exists for novel therapeutic strategies to manage PBC symptoms and disease progression.

Purpose of the Study:

• To review current and emerging drug candidates for primary biliary cholangitis.
• To explore potential future biological targets for PBC therapy.
• To discuss agents addressing both disease progression and symptom management, such as pruritus.

Main Methods:

• Literature review of preclinical and clinical studies on novel PBC therapies.
• Analysis of compounds targeting specific molecular pathways involved in cholestasis and inflammation.
• Examination of agents for symptomatic relief, particularly pruritus.

Main Results:

• Several drug classes are in development, including farnesoid X receptor/fibroblast growth factor 19 pathway modulators, peroxisome proliferator-activated receptor agonists, and transmembrane-G-protein-receptor-5 agonists.
• Immunological agents targeting specific inflammatory pathways are under investigation.
• Bile acid reuptake inhibitors, nalfurafine, and fibrates show promise for managing pruritus in PBC patients.

Conclusions:

• The pipeline for primary biliary cholangitis therapeutics is expanding with diverse pharmacological approaches.
• Targeting key signaling pathways and immune responses offers potential for improved disease control.
• Addressing debilitating symptoms like pruritus is a critical component of future PBC management strategies.